FR2887455B1 - Formulation a liberation prolongee de principes actifs de medicaments - Google Patents

Formulation a liberation prolongee de principes actifs de medicaments

Info

Publication number
FR2887455B1
FR2887455B1 FR0506539A FR0506539A FR2887455B1 FR 2887455 B1 FR2887455 B1 FR 2887455B1 FR 0506539 A FR0506539 A FR 0506539A FR 0506539 A FR0506539 A FR 0506539A FR 2887455 B1 FR2887455 B1 FR 2887455B1
Authority
FR
France
Prior art keywords
formulation
prolonged release
active medicinal
medicinal principles
principles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0506539A
Other languages
English (en)
Other versions
FR2887455A1 (fr
Inventor
Frederic Andre
Gerard Alaux
Gareth Lewis
Veronique Serre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35708770&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2887455(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Priority to FR0506539A priority Critical patent/FR2887455B1/fr
Priority to PA20068682701A priority patent/PA8682701A1/es
Priority to AU2006264856A priority patent/AU2006264856B2/en
Priority to KR1020077030484A priority patent/KR101387839B1/ko
Priority to NZ564069A priority patent/NZ564069A/en
Priority to MYPI20063017A priority patent/MY150069A/en
Priority to CA002611125A priority patent/CA2611125A1/fr
Priority to ZA200711035A priority patent/ZA200711035B/xx
Priority to EP06778663A priority patent/EP1904037A1/fr
Priority to EA200800150A priority patent/EA013745B1/ru
Priority to BRPI0612990-0A priority patent/BRPI0612990A2/pt
Priority to UAA200800914A priority patent/UA91553C2/ru
Priority to PCT/FR2006/001466 priority patent/WO2007003746A1/fr
Priority to MX2007016238A priority patent/MX2007016238A/es
Priority to DO2006000144A priority patent/DOP2006000144A/es
Priority to JP2008518906A priority patent/JP2008546830A/ja
Priority to CN2006800231372A priority patent/CN101217943B/zh
Priority to GT200600275A priority patent/GT200600275A/es
Priority to HN2006023741A priority patent/HN2006023741A/es
Priority to ARP060102755A priority patent/AR057410A1/es
Priority to PE2006000753A priority patent/PE20070098A1/es
Priority to TW095123267A priority patent/TWI446934B/zh
Priority to UY29637A priority patent/UY29637A1/es
Publication of FR2887455A1 publication Critical patent/FR2887455A1/fr
Application granted granted Critical
Publication of FR2887455B1 publication Critical patent/FR2887455B1/fr
Priority to TNP2007000438A priority patent/TNSN07438A1/en
Priority to US11/949,291 priority patent/US20080089936A1/en
Priority to IL187901A priority patent/IL187901A0/en
Priority to CR9567A priority patent/CR9567A/es
Priority to EC2007008010A priority patent/ECSP078010A/es
Priority to MA30501A priority patent/MA29560B1/fr
Priority to NO20080420A priority patent/NO20080420L/no
Priority to HK08114006.5A priority patent/HK1122731A1/xx
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR0506539A 2005-06-28 2005-06-28 Formulation a liberation prolongee de principes actifs de medicaments Expired - Fee Related FR2887455B1 (fr)

Priority Applications (31)

Application Number Priority Date Filing Date Title
FR0506539A FR2887455B1 (fr) 2005-06-28 2005-06-28 Formulation a liberation prolongee de principes actifs de medicaments
PA20068682701A PA8682701A1 (es) 2005-06-28 2006-06-23 Formulacion de liberación prolongada de principios activos de medicamentos
CN2006800231372A CN101217943B (zh) 2005-06-28 2006-06-26 药物活性组分的缓释剂型
KR1020077030484A KR101387839B1 (ko) 2005-06-28 2006-06-26 Ｐｈ-의존성 용해도를 갖는 활성 성분의 연장 방출형 제제
NZ564069A NZ564069A (en) 2005-06-28 2006-06-26 Prolonged release formulation of active principles having a pH-dependent solubility
MYPI20063017A MY150069A (en) 2005-06-28 2006-06-26 Formulation for prolonged release of active ingredients of medicaments
CA002611125A CA2611125A1 (fr) 2005-06-28 2006-06-26 Formulation a liberation prolongee de principes actifs de medicaments
ZA200711035A ZA200711035B (en) 2005-06-28 2006-06-26 Prolonged release formulation of active principles having a pH-dependent solubility
EP06778663A EP1904037A1 (fr) 2005-06-28 2006-06-26 Formulation a liberation prolongee de principes actifs presentant une solubilite dependante du ph
EA200800150A EA013745B1 (ru) 2005-06-28 2006-06-26 Состав с пролонгированным высвобождением, используемый с действующим началом, представляющим собой гемитартрат зольпидема
BRPI0612990-0A BRPI0612990A2 (pt) 2005-06-28 2006-06-26 formulação de liberação prolongada de princìpios ativos de medicamentos
UAA200800914A UA91553C2 (ru) 2005-06-28 2006-06-26 Состав с пролонгированным высвобождением гемитартрата зольпидема
PCT/FR2006/001466 WO2007003746A1 (fr) 2005-06-28 2006-06-26 Formulation a liberation prolongee de principes actifs presentant une solubilite dependante du ph
MX2007016238A MX2007016238A (es) 2005-06-28 2006-06-26 Formulacion de liberacion prolongada de principios activos que presentan una solubilidad dependiente de ph.
DO2006000144A DOP2006000144A (es) 2005-06-28 2006-06-26 Formulación de liberación prolongada de principios activos de medicamentos
JP2008518906A JP2008546830A (ja) 2005-06-28 2006-06-26 ｐＨ依存性の溶解度を有する有効成分の持続放出製剤
AU2006264856A AU2006264856B2 (en) 2005-06-28 2006-06-26 Prolonged release formulation of active principles having a pH-dependent solubility
HN2006023741A HN2006023741A (es) 2005-06-28 2006-06-27 " formulaciones de liberacion prolongada de principios activos de zolpidem hemitartrato"
ARP060102755A AR057410A1 (es) 2005-06-28 2006-06-27 Formulacion de liberacion prolongada de principios activos de medicamentos
GT200600275A GT200600275A (es) 2005-06-28 2006-06-27 Formulacion de liberacion prolongada de principios activos de medicamentos
PE2006000753A PE20070098A1 (es) 2005-06-28 2006-06-28 Formulacion de liberacion prolongada de principios activos que tienen solubilidad dependiente del ph
TW095123267A TWI446934B (zh) 2005-06-28 2006-06-28 供藥物之活性成份延長釋放之調配物
UY29637A UY29637A1 (es) 2005-06-28 2006-06-29 Formulación de liberación prolongada de principios activos de medicamentos
TNP2007000438A TNSN07438A1 (en) 2005-06-28 2007-11-26 Prolonged release formulation of active principles having a ph-dependent solubility
US11/949,291 US20080089936A1 (en) 2005-06-28 2007-12-03 Prolonged release formulation of active principles having a ph-dependent solubility
IL187901A IL187901A0 (en) 2005-06-28 2007-12-04 Prolonged release formulation of active principles having a ph-dependent solubility
CR9567A CR9567A (es) 2005-06-28 2007-12-06 Formulacion de liberacion prolongada de principios activos que presentan una solubilidad dependiente del ph
EC2007008010A ECSP078010A (es) 2005-06-28 2007-12-13 Formulación de liberación prolongada de principios activos que presentan una solubilidad dependiente del ph
MA30501A MA29560B1 (fr) 2005-06-28 2007-12-24 Formulation a liberation prolongee de principes actifs de medicaments
NO20080420A NO20080420L (no) 2005-06-28 2008-01-22 Formulering med forlenget frigivelse av aktive bestanddeler med pH-avhengig loselighet
HK08114006.5A HK1122731A1 (en) 2005-06-28 2008-12-29 Prolonged release formulation of active pharmaceutical ingredients

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0506539A FR2887455B1 (fr) 2005-06-28 2005-06-28 Formulation a liberation prolongee de principes actifs de medicaments

Publications (2)

Publication Number Publication Date
FR2887455A1 FR2887455A1 (fr) 2006-12-29
FR2887455B1 true FR2887455B1 (fr) 2007-08-10

Family

ID=35708770

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0506539A Expired - Fee Related FR2887455B1 (fr) 2005-06-28 2005-06-28 Formulation a liberation prolongee de principes actifs de medicaments

Country Status (31)

Country Link
US (1) US20080089936A1 (fr)
EP (1) EP1904037A1 (fr)
JP (1) JP2008546830A (fr)
KR (1) KR101387839B1 (fr)
CN (1) CN101217943B (fr)
AR (1) AR057410A1 (fr)
AU (1) AU2006264856B2 (fr)
BR (1) BRPI0612990A2 (fr)
CA (1) CA2611125A1 (fr)
CR (1) CR9567A (fr)
DO (1) DOP2006000144A (fr)
EA (1) EA013745B1 (fr)
EC (1) ECSP078010A (fr)
FR (1) FR2887455B1 (fr)
GT (1) GT200600275A (fr)
HK (1) HK1122731A1 (fr)
HN (1) HN2006023741A (fr)
IL (1) IL187901A0 (fr)
MA (1) MA29560B1 (fr)
MX (1) MX2007016238A (fr)
MY (1) MY150069A (fr)
NO (1) NO20080420L (fr)
NZ (1) NZ564069A (fr)
PA (1) PA8682701A1 (fr)
PE (1) PE20070098A1 (fr)
TN (1) TNSN07438A1 (fr)
TW (1) TWI446934B (fr)
UA (1) UA91553C2 (fr)
UY (1) UY29637A1 (fr)
WO (1) WO2007003746A1 (fr)
ZA (1) ZA200711035B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2090297A1 (fr) * 2008-02-13 2009-08-19 Boehringer Ingelheim International GmbH Formules de flibanserine
EA201490626A1 (ru) * 2011-09-14 2014-08-29 Поузен Инк. Поэтапное дозирование клопидогрела
IT201700011337A1 (it) * 2017-02-02 2018-08-02 S I I T S R L Servizio Int Imballaggi Termosaldanti Compressa multistrato per la somministrazione di magnesio

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2655266B1 (fr) * 1989-12-05 1992-04-03 Smith Kline French Lab Compositions pharmaceutiques a base de cimetidine.
EP0621777B1 (fr) * 1992-01-17 1996-09-11 ALFATEC-PHARMA GmbH Corps solides renfermant une matiere active, a structure composee de macromolecules hydrophiles, et leur procede de fabrication
EP1005863A1 (fr) * 1998-12-04 2000-06-07 Synthelabo Formes galeniques a liberation controlee contenant un hypnotique a activite courte ou un sel de ce compose
WO2000040205A2 (fr) * 1999-01-05 2000-07-13 Copley Pharmaceutical Inc. Formulation a liberation continue ayant une sensibilite limitee a l'humidite
EP1064937A1 (fr) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Formes pharmaceutiques à liberation controllée comprenant un hypnotique à courte duree ou une des ses sels
JP4933033B2 (ja) * 2003-03-17 2012-05-16 武田薬品工業株式会社 放出制御組成物
AU2004287485A1 (en) * 2003-11-05 2005-05-19 Santarus, Inc. Combination of proton pump inhibitor and sleep aid

Also Published As

Publication number Publication date
NO20080420L (no) 2008-01-22
TWI446934B (zh) 2014-08-01
EA013745B1 (ru) 2010-06-30
CN101217943B (zh) 2012-05-23
JP2008546830A (ja) 2008-12-25
AU2006264856B2 (en) 2011-09-15
FR2887455A1 (fr) 2006-12-29
US20080089936A1 (en) 2008-04-17
KR20080019023A (ko) 2008-02-29
GT200600275A (es) 2007-03-29
UA91553C2 (ru) 2010-08-10
TW200727921A (en) 2007-08-01
HK1122731A1 (en) 2009-05-29
NZ564069A (en) 2012-04-27
EA200800150A1 (ru) 2008-04-28
BRPI0612990A2 (pt) 2011-04-19
MY150069A (en) 2013-11-29
MX2007016238A (es) 2008-03-06
CR9567A (es) 2008-02-20
WO2007003746A1 (fr) 2007-01-11
KR101387839B1 (ko) 2014-04-22
CN101217943A (zh) 2008-07-09
PE20070098A1 (es) 2007-03-01
HN2006023741A (es) 2011-05-31
MA29560B1 (fr) 2008-06-02
TNSN07438A1 (en) 2009-03-17
EP1904037A1 (fr) 2008-04-02
ECSP078010A (es) 2008-01-23
PA8682701A1 (es) 2007-01-17
IL187901A0 (en) 2008-03-20
CA2611125A1 (fr) 2007-01-11
DOP2006000144A (es) 2007-02-28
ZA200711035B (en) 2009-09-30
AU2006264856A1 (en) 2007-01-11
UY29637A1 (es) 2007-01-31
AR057410A1 (es) 2007-12-05

Similar Documents

Publication Publication Date Title
HRP20181819T1 (hr) Formulacija krutog farmaceutskog oblika doziranja koja sadrži lopinavir
CU20080052A7 (es) Formas de presentación farmacéutica sólidas de administración oral con liberación rápida de principio activo
DK2073795T3 (da) Misbrugssikret lægemiddelformulation
FR2901478B1 (fr) Forme pharmaceutique orale multimicroparticulaire a liberation prolongee
HK1121970A1 (en) Sustained release pharmaceutical formulation comprising phenylephrine
JP2008539179A5 (ja) 殺虫活性物質併用の組み合わせ
EP2081550A4 (fr) Revêtement de capsules avec des ingrédients pharmaceutiques actifs
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
BRPI0915093A2 (pt) conjugados para a administração de compostos biologicamente ativos
BRPI0507225A2 (pt) formulações estáveis de solução farmacêutica para inaladores pressurizados de dose medida
BRPI0719394A2 (pt) Preparação medicinal sólida
PL1795186T5 (pl) Preparat leku zawierający flupirtynę o kontrolowanym uwalnianiu substancji czynnej
FR2934156B1 (fr) Medicament appetissant a administration orale sous forme solide
BRPI1009392A2 (pt) "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica."
IL201465A0 (en) Self-precipitating pharmaceutical formulations for the modified release of active principle
DK2918286T3 (da) En farmaceutisk formulering
FR2873294B1 (fr) Association de medicaments
FR2887455B1 (fr) Formulation a liberation prolongee de principes actifs de medicaments
BRPI0810878A2 (pt) Partículas à base de polieletrólitos e de princípio ativo de liberação modificada e formulações farmacêuticas contendo estas partículas.
BRPI0913709A2 (pt) "formulação farmacêutica"
PL1848439T3 (pl) Doustna formulacja o natychmiastowym uwalnianiu słabo rozpuszczalnej w wodzie substancji aktywnej
ATE530164T1 (de) Wässrige pharmazeutische zubereitung
ZA200806950B (en) Medicinal formulation containing a combination of HIV TYPE I and HIV TYPE II
GB0610207D0 (en) New forms of active pharmaceutical ingredient
JP2010090042A5 (fr)

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 16

ST Notification of lapse

Effective date: 20220205